Global Automated and Closed Cell Therapy Processing Systems Market Revenue Grows at a CAGR of 18.62%.

Introduction

Straits Research released its highly anticipated report, “Global Automated and Closed Cell Therapy Processing Systems Market Size & Outlook, 2026-2034”. According to the study, the market size is valued at USD 1.64 billion in 2025 and is projected to expand to USD 7.61 billion by 2034, registering a compound annual growth rate (CAGR) of 18.62%.

Market Dynamics

The automated and closed cell therapy processing systems market is gaining strong momentum as the demand for scalable, standardized, and contamination-free manufacturing solutions for advanced therapies accelerates. A key driver stimulating market expansion is the rising global adoption of cell-based therapeutics, such as CAR-T, stem-cell, and gene-modified treatments, which require high precision, GMP-compliant processing platforms. As healthcare systems increasingly shift toward personalized and regenerative medicine, manufacturers are prioritizing automated, closed systems to improve consistency, reduce manual handling errors, and enable faster transition from clinical development to commercial production. This growing therapeutic pipeline is prompting biopharmaceutical companies and CDMOs to adopt integrated processing technologies capable of supporting reliable, high-throughput workflows.

However, the market faces a notable restraint in the form of high capital investment. Automated and fully closed cell therapy systems involve substantial upfront costs related to equipment procurement, facility integration, consumables, and maintenance. These financial barriers are challenging for smaller biotech firms and research institutes operating with limited budgets, slowing early-stage adoption.

Despite these constraints, a major opportunity lies in the expanding focus on allogeneic, off-the-shelf cell therapies. As these products move closer to commercialization, demand for large-scale, standardized bioprocessing solutions is rising rapidly. Automated closed systems offer an ideal pathway for industrialized manufacturing, providing the scalability, reproducibility, and regulatory compliance needed to support high-volume production. This shift toward allogeneic platforms is expected to unlock substantial growth potential for technology developers worldwide.

Market Highlights

• Workflow: The separation segment dominated the market in 2025, accounting for 32.55% revenue share.
• Type: The stem cell therapy segment is estimated to grow at the fastest pace with a CAGR of 19.62%.
• Scale: The R&D scale segment dominated the market in 2025, owing to the rising number of academic and industry-led research programs.
• Regional Insights: North America dominated the market, accounting for 49.84% of market share in 2025, due to robust investments in regenerative medicine.

Competitive Players

1. Bio-Rad Laboratories
2. BioSpherix, LLC
3. CELLARES
4. CellGenix GmbH
5. Corning Incorporated
6. Danaher Corporation
7. Eppendorf AG
8. Fresenius Kabi
9. MaxCyte
10. GE Healthcare
11. Lonza
12. Merck KGaA
13. Miltenyi Biotec
14. Sartorius AG
15. Terumo Corporation
16. Thermo Fisher Scientific Inc.
17. ThermoGenesis Holdings, Inc.
18. Wuxi AppTec
19. Others

Recent Developments

September 2025: Multiply Labs, a robotics company, collaborated with Thermo Fisher Scientific for integrating Thermo Fisher’s automated Gibco CTS DynaCellect Magnetic Separation System with Multiply Labs’ state-of-the-art robotic platforms. 

Segmentation

1. By Workflow (2026-2034)
   1. Separation
   2. Expansion
   3. Apheresis
   4. Fill- Finish
   5. Cryopreservation
   6. Others
2. By Type (2026-2034)
   1. Stem Cell Therapy
   2. Non-Stem Cell Therapy
3. By Scale (2026-2034)
   1. R&D Scale
   2. Commercial Scale